Sleep Medicine Resource Utilization in Individuals With Parkinson Disease: A Population Study of Health Administrative Data.

IF 3.2 Q3 CLINICAL NEUROLOGY
Neurology. Clinical practice Pub Date : 2025-08-01 Epub Date: 2025-07-11 DOI:10.1212/CPJ.0000000000200511
Ryan Gotfrit, Robert Talarico, Priti Gros, Marta Kaminska, Tiago A Mestre, Tetyana Kendzerska
{"title":"Sleep Medicine Resource Utilization in Individuals With Parkinson Disease: A Population Study of Health Administrative Data.","authors":"Ryan Gotfrit, Robert Talarico, Priti Gros, Marta Kaminska, Tiago A Mestre, Tetyana Kendzerska","doi":"10.1212/CPJ.0000000000200511","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Individuals with Parkinson disease (PD) may face barriers in obstructive sleep apnea diagnosis/management due to sleep being lower priority and sleep disturbances being poorly recognized. Evidence on sleep-medicine service utilization in the PD population is lacking. We conducted a population-based study to identify discrepancies in sleep-medicine resource use (prevalence rates of polysomnograms [PSG] performed and positive airway pressure [PAP] initiated) over a 10-year period between the PD population and the matched non-PD population.</p><p><strong>Methods: </strong>We conducted a retrospective longitudinal population-based study using health administrative databases in Ontario from 2012 to 2021 in adults with PD to compare overall and annual prevalence rates of PSGs performed and PAP initiated to 1:1 randomly selected propensity score matched controls from the matched non-PD population based on simultaneous exact matching on age, sex, and calendar year and caliper matched propensity scores from a logistic regression model (based on sociodemographic variables and comorbidities) using validated health administrative definitions to identify PD cases and controls. We hypothesized that the PD population has lower rates of PSGs performed and PAP treatments initiated compared with the similar matched non-PD population. We used Poisson regression to estimate annual prevalence rate ratios to determine the relative change in prevalence over the study period between the groups.</p><p><strong>Results: </strong>Sixty-five thousand, one hundred sixty-seven patients with PD and 11,460,672 controls met our inclusion criteria. We successfully propensity score matched 64,879 PD cases to controls. From 2012 to 2021, there were a higher prevalence of any PSG performed in the PD population (8.2% vs 6.3%, [RR: 1.30, 95% CI: 1.25-1.35], <i>p</i> < 0.001) and no difference in the rates of any PAP initiated in the PD population vs controls (4.0% vs 4.1%, [RR: 0.93-1.03, 95% CI: 0.93-1.03], <i>p</i> = 0.46). For both groups, annual prevalence rates generally increased over time. There was no difference in the annual prevalence rate ratio of any PSG performed or any PAP initiated in the PD population vs controls (1.07 [95% CI: 1.06-1.07] vs 1.07 [95% CI: 1.07-1.08], <i>p</i> = 0.5; 1.10 [95% CI: 1.09-1.11] vs 1.11 [95% CI: 1.10-1.11], <i>p</i> = 0.18, respectively).</p><p><strong>Discussion: </strong>Sleep-medicine resource utilization in the PD population is at least similar to the matched non-PD population and follows the increase with time observed in the general population.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 4","pages":"e200511"},"PeriodicalIF":3.2000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12253960/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Individuals with Parkinson disease (PD) may face barriers in obstructive sleep apnea diagnosis/management due to sleep being lower priority and sleep disturbances being poorly recognized. Evidence on sleep-medicine service utilization in the PD population is lacking. We conducted a population-based study to identify discrepancies in sleep-medicine resource use (prevalence rates of polysomnograms [PSG] performed and positive airway pressure [PAP] initiated) over a 10-year period between the PD population and the matched non-PD population.

Methods: We conducted a retrospective longitudinal population-based study using health administrative databases in Ontario from 2012 to 2021 in adults with PD to compare overall and annual prevalence rates of PSGs performed and PAP initiated to 1:1 randomly selected propensity score matched controls from the matched non-PD population based on simultaneous exact matching on age, sex, and calendar year and caliper matched propensity scores from a logistic regression model (based on sociodemographic variables and comorbidities) using validated health administrative definitions to identify PD cases and controls. We hypothesized that the PD population has lower rates of PSGs performed and PAP treatments initiated compared with the similar matched non-PD population. We used Poisson regression to estimate annual prevalence rate ratios to determine the relative change in prevalence over the study period between the groups.

Results: Sixty-five thousand, one hundred sixty-seven patients with PD and 11,460,672 controls met our inclusion criteria. We successfully propensity score matched 64,879 PD cases to controls. From 2012 to 2021, there were a higher prevalence of any PSG performed in the PD population (8.2% vs 6.3%, [RR: 1.30, 95% CI: 1.25-1.35], p < 0.001) and no difference in the rates of any PAP initiated in the PD population vs controls (4.0% vs 4.1%, [RR: 0.93-1.03, 95% CI: 0.93-1.03], p = 0.46). For both groups, annual prevalence rates generally increased over time. There was no difference in the annual prevalence rate ratio of any PSG performed or any PAP initiated in the PD population vs controls (1.07 [95% CI: 1.06-1.07] vs 1.07 [95% CI: 1.07-1.08], p = 0.5; 1.10 [95% CI: 1.09-1.11] vs 1.11 [95% CI: 1.10-1.11], p = 0.18, respectively).

Discussion: Sleep-medicine resource utilization in the PD population is at least similar to the matched non-PD population and follows the increase with time observed in the general population.

帕金森病患者睡眠药物资源利用:一项健康管理数据的人口研究
背景和目的:帕金森病(PD)患者在阻塞性睡眠呼吸暂停诊断/管理方面可能面临障碍,因为睡眠不被优先考虑,睡眠障碍未被充分认识。缺乏PD人群睡眠药物服务使用的证据。我们进行了一项基于人群的研究,以确定PD人群和匹配的非PD人群在10年期间睡眠药物资源使用的差异(进行多导睡眠图[PSG]和气道正压[PAP]启动的患病率)。方法:我们利用安大略省2012年至2021年的卫生管理数据库,对成年PD患者进行了一项回顾性的纵向人群研究,以比较进行psg和启动PAP的总体和年患病率与1:1随机选择的倾向评分匹配的对照,这些对照来自匹配的非PD人群,基于年龄、性别、日历年和卡尺匹配逻辑回归模型(基于社会人口学变量和合并症)的倾向得分,使用经过验证的健康管理定义来识别PD病例和对照。我们假设,与相似匹配的非PD人群相比,PD人群进行psg和PAP治疗的比例较低。我们使用泊松回归来估计年患病率比率,以确定研究期间各组之间患病率的相对变化。结果:65000 167例PD患者和11460672例对照符合我们的纳入标准。我们成功地将64,879例PD病例与对照组相匹配。从2012年到2021年,PD人群中PSG的患病率较高(8.2% vs 6.3%, [RR: 1.30, 95% CI: 1.25-1.35], p < 0.001), PD人群中PAP的发生率与对照组无差异(4.0% vs 4.1%, [RR: 0.93-1.03, 95% CI: 0.93-1.03], p = 0.46)。对于这两组,年患病率通常随着时间的推移而增加。PD人群中进行PSG或启动PAP的年患病率比与对照组无差异(1.07 [95% CI: 1.06-1.07] vs 1.07 [95% CI: 1.07-1.08], p = 0.5;1.10 [95% CI: 1.09-1.11] vs 1.11 [95% CI: 1.10-1.11], p = 0.18)。讨论:PD人群的睡眠药物资源利用率至少与匹配的非PD人群相似,并且在一般人群中观察到随着时间的推移而增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurology. Clinical practice
Neurology. Clinical practice CLINICAL NEUROLOGY-
CiteScore
4.00
自引率
0.00%
发文量
77
期刊介绍: Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信